23Strands has signed an agreement with Datar Cancer Genetics to sell Datar's proven protocol for deep genomics driven cancer therapy optimisation.

"This agreement will make it easier for Australian patients to get access to more personalised and effective treatments for those patients who have limited options once first line treatments fail" said Mark Grosser CEO 23Strands.